243 related articles for article (PubMed ID: 25333254)
21. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice.
Welschinger R; Liedtke F; Basnett J; Dela Pena A; Juarez JG; Bradstock KF; Bendall LJ
Exp Hematol; 2013 Mar; 41(3):293-302.e1. PubMed ID: 23178377
[TBL] [Abstract][Full Text] [Related]
22. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer.
Heckmann D; Maier P; Laufs S; Li L; Sleeman JP; Trunk MJ; Leupold JH; Wenz F; Zeller WJ; Fruehauf S; Allgayer H
Clin Cancer Res; 2014 Feb; 20(3):604-16. PubMed ID: 24255072
[TBL] [Abstract][Full Text] [Related]
23. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
Juarez J; Dela Pena A; Baraz R; Hewson J; Khoo M; Cisterne A; Fricker S; Fujii N; Bradstock KF; Bendall LJ
Leukemia; 2007 Jun; 21(6):1249-57. PubMed ID: 17410186
[TBL] [Abstract][Full Text] [Related]
24. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
[TBL] [Abstract][Full Text] [Related]
25. CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
Jin CH; Li Y; Xia J; Li Y; Chen M; Hu Z; Mapara MY; Li W; Yang YG
Am J Hematol; 2018 Jun; 93(6):786-793. PubMed ID: 29603337
[TBL] [Abstract][Full Text] [Related]
26. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow.
Shen W; Bendall LJ; Gottlieb DJ; Bradstock KF
Exp Hematol; 2001 Dec; 29(12):1439-47. PubMed ID: 11750103
[TBL] [Abstract][Full Text] [Related]
27. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Uy GL; Rettig MP; Motabi IH; McFarland K; Trinkaus KM; Hladnik LM; Kulkarni S; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Vij R; Westervelt P; DiPersio JF
Blood; 2012 Apr; 119(17):3917-24. PubMed ID: 22308295
[TBL] [Abstract][Full Text] [Related]
28. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers.
Bradstock KF; Makrynikola V; Bianchi A; Shen W; Hewson J; Gottlieb DJ
Leukemia; 2000 May; 14(5):882-8. PubMed ID: 10803521
[TBL] [Abstract][Full Text] [Related]
29. Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.
Goodrich AD; Varain NM; Jeanblanc CM; Colon DM; Kim J; Zanjani ED; Hematti P
Cytotherapy; 2014 Sep; 16(9):1280-93. PubMed ID: 25108653
[TBL] [Abstract][Full Text] [Related]
30. Cathepsin K cleavage of SDF-1α inhibits its chemotactic activity towards glioblastoma stem-like cells.
Hira VV; Verbovšek U; Breznik B; Srdič M; Novinec M; Kakar H; Wormer J; der Swaan BV; Lenarčič B; Juliano L; Mehta S; Van Noorden CJ; Lah TT
Biochim Biophys Acta Mol Cell Res; 2017 Mar; 1864(3):594-603. PubMed ID: 28040478
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
32. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
33. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
34. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells.
Hidalgo A; Sanz-Rodríguez F; Rodríguez-Fernández JL; Albella B; Blaya C; Wright N; Cabañas C; Prósper F; Gutierrez-Ramos JC; Teixidó J
Exp Hematol; 2001 Mar; 29(3):345-55. PubMed ID: 11274763
[TBL] [Abstract][Full Text] [Related]
35. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
36. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
[TBL] [Abstract][Full Text] [Related]
37. [Effects of SDF-1/CXCR4 signal pathway blockade by AMD3100 on the adhesion of leukemia cells to osteoblast niche and the drug resistance of leukemia cells].
Shen Z; Zeng D; Zou Z; Zhu L; Ma Y; Zhang X; Zhang C; Li J; Kong P
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):413-7. PubMed ID: 26031530
[TBL] [Abstract][Full Text] [Related]
38. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
39. Stromal cell-derived factor-1 exerts opposing roles through CXCR4 and CXCR7 in angiotensin II-induced adventitial remodeling.
Song B; Chen D; Liu Z; Cheng Y; Zhang Z; Han W; Zhang R; Gong Y
Biochem Biophys Res Commun; 2022 Feb; 594():38-45. PubMed ID: 35066378
[TBL] [Abstract][Full Text] [Related]
40. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.
Wuchter P; Leinweber C; Saffrich R; Hanke M; Eckstein V; Ho AD; Grunze M; Rosenhahn A
Cell Tissue Res; 2014 Feb; 355(2):315-26. PubMed ID: 24337688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
